As if enough start-ups haven't struggled to go public this year, one company has decided to proceed with its plans to go public—this week. Fluidigm, a biotech company, plans to make its public offering tomorrow barring the possibility that it's forced to withdraw. Considering what's happened in the markets the past few days, it's a real possibility.

"This is terrible timing for this company." Scott Sweet, a senior managing partner at the research and advisory firm I.P.O. Boutique, told the New York Times.

If the Fluidigm IPO manages to go down, it will only be the seventh VC-backed start-up to go public this year. Yet, regardless of what happens in the markets, Fluidigm's sale still might not be pretty. The company experienced more than $25 million in net losses on $7 million in revenues, and they say they expect that trend to continue. What's worse (particularly if you're a superstitious type) is that Rackspace and GT Solar, the last two public offerings this year, have bombed.

So who's ready to buy?